Breadcrumb

Cancer Enterprise Global Pipeline

Daiichi Sankyo Cancer Enterprise Global Pipeline

As of May 2017

These are investigational agents and are not approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.

ADC Franchise

 

Compound Tumor Type Tumor Expressing Highest Phase of Development Location
DS-8201

Breast Cancer

Gastric Cancer

HER2

Phase 1

US / Japan

U3-1402

Breast Cancer

HER3

Phase 1

Japan

DS-7300

Solid Tumors

B7-H3

Preclinical

--

DS-1062

Solid Tumors

TROP2

Preclinical

--

Project 5

Solid Tumors

Undisclosed

Preclinical

--

Project 6

Solid Tumors

Undisclosed

Preclinical

--

 

AML Franchise

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location

Quizartinib (AC220)

Newly-Diagnosed Acute Myeloid Leukemia (AML)

FLT3

Phase 3

US / EU/ Asia

Quizartinib (AC220)

Relapsed/Refractory AML

FLT3

Phase 3

US / EU/ Asia

Quizartinib (AC220)

Relapsed/Refractory AML

FLT3

Phase 1

Japan

DS-3032

AML, Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome (MDS)

MDM2

Phase 1

US

DS-3032

Solid Tumors, Lymphoma

MDM2

Phase 1

Japan

DS-3201

AML, ALL

EZH1/2

Phase 1

US

DS-3201

Non-Hodgkin’s Lymphoma

EZH1/2

Phase 1

Japan

PLX51107

AML, MDS, Lymphoma, Solid Tumors

BRD4

Phase 1

US

DS-1001

AML

IDH1

Preclinical

--

 

Additional Late and Early Stage Programs

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location

Pexidartinib (PLX3397)

Tenosynovial Giant Cell Tumor (TGCT)* FDA Breakthrough Designation

CSF-1R

Phase 3

US / EU

Pexidartinib (PLX3397)

Glioblastoma

CSF-1R

c-KIT

Phase 2

US

Pexidartinib (PLX3397)

Melanoma

c-KIT

Phase 1/2

Asia

Pexidartinib (PLX3397)

Solid Tumors

CSF-1R

Phase 1

Asia

Pexidartinib (PLX3397)

Solid Tumors, Melanoma

CSF-1R

Phase 1/2

US

Pexidartinib (PLX3397) [in combination with pembrolizumab]

Solid Tumors, Melanoma

CSF-1R

Phase 1/2

US

Patritumab (U3-1287)

Head and Neck Cancer

HER3

Phase 2

EU

DS-1647

Glioblastoma SAKIGAKE Designation

Oncolytic HSV-1

Phase 2

Japan

PLX7486

Solid Tumors

FMS/TRK

Phase 1

US

PLX8394

Solid Tumors

BRAF

Phase 1

US

DS-8273

Solid Tumors

DR5

Phase 1

US

DS-6051

Solid Tumors

NTRK/ROS1

Phase 1

US / Japan

PLX9486

Solid Tumors

KIT

Phase 1

US

PLX73086

TGCT

CSF-1R

Phase 1

US

DS-1123

Solid Tumors

FGFR2

Phase 1

Japan

DS-1001

Gliomas

IDH1

Phase 1

Japan

*Tenosynovial giant cell tumor (TGCT), which includes pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS).

 

Oncology more stories content

More Stories

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer.

read more ...